Bide Pharmatech Co Ltd. Stock Analysis 688073.SS

Bide Pharmatech Co., Ltd. engages in the research, development, design, production and sales of drug molecular building blocks. The company is headquartered in Shanghai, Shanghai and currently employs 734 full-time employees. The company went IPO on 2022-10-11. The firm is mainly engaged in the research, development, production, and sales of drug molecular building blocks and scientific reagents, serving key stages of new drug research and development. The firm's main products are pharmaceutical molecular building blocks and scientific reagents. The firm's products are mainly applied in drug target discovery, lead compound synthesis and screening, lead compound discovery, synthesis and optimization, and other stages of new drug research and development. The firm mainly operates in the domestic and overseas markets.